key: cord-0824667-iwtf8kmm
authors: Fanshawe, Jack; Howell, Jack; Omar, Adhnan; Piper, Megan; Simpson, Thomas
title: Corticosteroids and pulmonary rehabilitation reducing long‐term morbidity in a patient with post‐COVID‐19 pneumonitis: A case study
date: 2021-03-13
journal: Physiother Res Int
DOI: 10.1002/pri.1903
sha: 3d607512c90b1ea76e8766f71c00f12853288052
doc_id: 824667
cord_uid: iwtf8kmm

BACKGROUND: Whilst research efforts have focussed on treatment during the acute phase, little work has focussed on the long‐term sequelae of COVID‐19 infection. This case described a patient who remained symptomatic several weeks after discharge from hospital with what was diagnosed as a COVID‐19 infection. There were significant deficits shown in his functional exercise testing, his pulmonary functions testing and there was evidence of fibrotic changes on his radiology. METHODS: As part of a multidisciplinary clinic, he was started on steroids and a tailored pulmonary rehabilitation course over a course of 6–8 weeks. Thereafter, his exercise testing, pulmonary function tests and radiology were all repeated to see progress. RESULTS: On completing the course of corticosteroids and concurrent personalised pulmonary rehabilitation, there was a dramatic improvement in the patient's symptom severity, radiology and pulmonary function. The most significant improvement noted was in his exercise testing, namely a 6‐min walk test and 1 min of sit‐to‐stands. Before treatment, he had a Medical Reserch Council (MRC) score of 2, and after it returned to his baseline of 0. DISCUSSION: Using corticosteroids and exercise training that allowed quantitative evaluation throughout the stages of recovery was a valuable tool to gauge progress and response to treatment. These therapies present opportunity to prevent the development of irreversible pulmonary fibrosis that could prove to be a major breakthrough in reducing long‐term morbidity and improving the quality of life of those affected.

been noted as a long-term sequelae of coronavirus infection in the past two major outbreaks of viruses in this family: severe acute respiratory syndrome (SARS) and middle eastern respiratroy syndrome (MERS) (Das et al., 2017; Xie et al., 2005) . This condition affects patients' quality of life and also infers increased risk of early mortality (Brown et al., 2020; Ojo et al., 2020) When previously given during active infection for SARS and MERS, corticosteroids led to enhanced viral replication, reduced viral clearance and had no positive effect on survival (Arabi et al., 2018; Stockman et al., 2006) . Yet conversely, the use of methylprednisolone reduced lung remodelling and eventual mortality in those patients that progress to acute respiratory distress syndrome from infection (Gentile et al., 2020; Wu et al., 2020) . Furthermore, it is thought that extended courses of low-dose corticosteroids may reduce lung remodelling in post-COVID-19 patients (Gentile et al., 2020) . Randomised control trials are currently being conducted to establish the efficacy of prednisolone in treating post-COVID-19 fibrosis (Rashad, 2020) . Pulmonary rehabilitation programmes have been shown to improve exercise capacity, dyspnoea and quality of life in those interstitial lung disease and idiopathic pulmonary fibrosis (Dowman et al., 2014) . Early guidance from China advocated for pulmonary rehabilitation in COVID-19 survivors .

A 51-year-old gentleman presented to a London District General Hospital during the COVID-19 pandemic with 1-week history of fatigue, dry cough and worsening dyspnoea.

His medical history included hypertension and chronic kidney disease stage 2. At his functional baseline, he was independent. He did not smoke or drink alcohol and had an MRC dyspnoea score of 0.

At his baseline exercise tolerance, he would regularly run a distance of 5 km up to three times a week and would also carry out a homebased exercise workout once a week.

On examination at admission, he was haemodynamically stable and was maintaining saturations on 2 L of oxygen via nasal cannula. A chest x-ray (CXR) demonstrated slight coarsening of bronchovascular markings but no acute consolidation, effusion or collapse. The arterial blood gas (ABG) on 2 L showed pH 7.48, pCO 2 5.93 and pO 2 11.2. He was commenced on IV antibiotics for suspected superadded bacterial infection. His laboratory results revealed a raised C-reactive protein (CRP), slight increase in creatinine from baseline and a lymphopenia.

His notable haematology and biochemistry results throughout the case are displayed in Table 1 .

On day 2, he developed a rapidly increasing oxygen requirement and a worsening type 2 respiratory failure (T2RF), pH 7.445, pCO 2 6.53 and pO 2 10.4. His first COVID-19 viral PCR swab, sputum and blood cultures, as well as an atypical pneumonia screen all returned negative.

On day 8, his oxygen requirement further increased to 15L via a non-rebreathe mask (NRB) and an arterial gas showed a further deteriorating T2RF pH 7.451, pCO 2 6.27, pO 2 9.38 and HCO 3 31.2.

His antibiotics were escalated, and he was referred to critical care who reviewed him on day 9 and believed he did not require admission to intensive care. A repeat COVID-19 PCR swab again returned negative.

He continued to require 15 L NRB for further 2 days after which his oxygenation began to improve. Inpatient physiotherapy teams taught breathlessness management, educated him on oxygen delivery and stressed the need for early mobilisation.

His oxygen was slowly able to be titrated, and on repeat physiotherapy assessment, he was able to demonstrate maintenance of his independent function and mobility despite his increased oxygen demand and prolonged admission. He was, therefore, discharged from physiotherapy with no acute inpatient therapy needs identified.

He was successfully weaned entirely off oxygen over the next 3 days, maintaining saturations on room air after 16 days of admission. He was then discharged with follow-up imaging, pulmonary function testing and to be followed up in a multidisciplinary post-COVID clinic.

Despite the absence of a positive COVID-19 PCR, this was still deemed a COVID-19 infection owing to the presentation during the peak surge in our hospital, high clinical suspicion, consistent radiology and biochemistry, and absence of evidence for other precipitating causes.

This gentleman was reviewed in the post-COVID-19 clinic 6 weeks post-discharge. He reported slowly resolving fatigue and breathlessness. His MRC dyspnoea scale was now 2 from a baseline of 0. A CXR showed significant resolution of the COVID-19 pneumonitis with persistent volume loss and early fibrotic changes. It was also noted that he had returned to work at a reduced capacity and hours due to his ongoing symptoms.

He had a thorough physiotherapy assessment that included a sitto-stand test and the 6-min walk test (6MWT). He also completed the FACIT-Dyspnoea Scale 10-item Short Form of which he scored 19/60 reporting severe shortness of breath on 'walking for ½ mile without stopping' and moderate shortness of breath on 'walking up 20 stairs without stopping' and completing household activities such as 'sweeping or mopping' as per the outcome measure. Throughout the testing monitoring of objective markers including saturations (SpO 2 ), heart rate (HR) and respiratory rate (RR) were taken. In addition to this, a score on the Modified Borg Dyspnoea RPE scale and a 0-10 'fatigue of legs' scale were taken at rest and post-testing. Time to recover to baseline resting observations and RPE were also measured. Time was given between the two tests as per the trust Standard Operating Procedure for exercise testing in post-COVID-19 patients.

For the 6MWT, he achieved a total distance of 490 m. During the testing, we recorded a significant acute desaturation of 8% from 98% to 90%. His saturations then took 50 s to recover to be within normal resting range (>96%). His HR rose from 89 beats per minute (bpm) to 138 bpm during testing and reached this peak at his greatest desaturation. He had a raised resting respiratory rate of 24, which rose to 26 on testing; however, he recovered quickly. His cardiovascular response to the exercise testing took a total of 5 min to recover posttesting. He also reported a perceived exertion of 'moderate' (3) on the Modified Borg Dyspnoea RPE scale throughout the testing which was 'nothing at all' (0) at rest.

He achieved a total of 23 sit-to*stands in 1 min. For comparison, the median number for his age group would be 50 (Strassmann et al., 2013) . His saturations were from 97% at rest to 91% during the assessment, and it then took 45 s for his saturations to recover to baseline. His RPE went from 'nothing at all' (0) at rest to 'very severe' 

This gentleman was then reviewed at 12-week post-discharge and due to his poor physiotherapy outcomes, established fibrosis on HRCT and reduced lung volumes and transfer factor, he was commenced on a 3-week course of oral prednisolone (30 mg OD for 7 days, 20 mg OD for 7 days, 10 mg OD for 7 days).

On completion of this initial course of steroids, he was then re-assessed by our physiotherapy team and repeated the previous 6MWT and 1-min sit-to-stand test. He scored 0/60 on the FACIT-Dyspnoea Scale 10 item short form. He reported having increased his work capacity and hours and was close to returning to full time.

For his 6MWT, he had a significant increase of 155 m compared to his previous test. Desaturation did occur, although only reduced by 5% from 98% to 93%. Max HR was 130 bpm with a much faster recovery of 2 min and 20 s to return to baseline. This was also the time it took for his RPE and fatigue scores to recover to baseline of 'nothing at all' (0) from 'moderate to severe' (4).

For his 1-min sit-to-stand test, he was able to achieve 37 sit-tostands, which is a significant increase of 14 sit-to-stands. He did again, desaturate from 98% to 93%. Overall, his recovery was within 2 min and 50 s for all subjective and objective markers. His RPE was reduced from a previous 'very severe' (7) to at a 'severe' (5) on retesting which was in keeping with the self-reported improved fitness and conditioning levels.

He was therefore able to achieve a significant increase in distance walked, sit-to-stands achieved and recovery time for subjective and objective markers. The distance walked and sit-to- This retesting showed considerable improvement although he continued to acutely desaturate. It was decided that he would be continued on a further 4-week course of prednisolone 10 mg OD.

Repeat PFTs at 12-week post-discharge ( Figure 1 ) demonstrated a marked improvement from his initial testing; FEV 1 was 2.73 (80% of predicted), FVC was 3.19 (75% of predicted) and TLCO was 7.21 (74% of predicted). A repeat HRCT (Figure 2b ) at 12-week postdischarge showed partial resolution of the previously noted fibrosis and ground glass opacifications. Residual fibrosis and mild traction bronchiectasis were seen scattered peripherally in both lung fields.

However, both modalities confirmed notable improvement documented after repeat exercise testing.

He was referred to pulmonary rehabilitation following his initial assessment in the post-COVID-19 clinic. The course commenced 8 weeks after discharge for 8 weeks where he was also given guid- The authors acknowledge that it is difficult to prove causality from this single case. If further studies replicated the results seen in this report, the use of corticosteroids and pulmonary rehabilitation in those with ongoing COVID-19 associated pneumonitis, to prevent the development of irreversible pulmonary fibrosis, could prove to be a major breakthrough in reducing long-term morbidity and improving the quality of life of those affected.

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

F I G U R E 3 Timeline of significant events FANSHAWE ET AL.

Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome

Safety and feasibility of an exercise prescription approach to rehabilitation across the continuum of care for survivors of critical illness

The natural history of progressive fibrosing interstitial lung diseases

Follow-up chest radiographic findings in patients with MERS-CoV after recovery

Pulmonary rehabilitation for interstitial lung disease

Silent hypoxia in patients with SARS CoV-2 infection before hospital discharge

COVID-19 and risk of pulmonary fibrosis: The importance of planning ahead

Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies

Post COVID-19 pulmonary fibrosis-Is it reversible?

Short term low dose corticosteroids for management of post covid-19 pulmonary fibrosis

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. The Lancet Infectious Diseases

Sars: Systematic review of treatment effects

Population-based reference values for the 1-min sit-to-stand test

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge

Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID-19). Chronic Diseases and Translational

Corticosteroids and pulmonary rehabilitation reducing long-term morbidity in a patient with post-COVID-19 pneumonitis: A case study

The authors have no conflicts of interest relevant to this article to disclose.

Adhnan Omar, Jack Fanshawe and Jack Howell drafted and revised the manuscript. Thomas Simpson, Jack Howel and Megan Piper were all involved in the care given to the patient. Thomas Simpson critically revised the manuscript and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Ethical approval not required for this report, and patient written consent obtained.

The data that support the findings of this study are available on request from the corresponding author.

https://orcid.org/0000-0001-5667-0263